GenMont BiotechTPE:3164 +0.30%82 Net Margin % is 24.62% as of Dec. 2025, which is 62% above its 10-year median of 15.16. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 937 Biotechnology companies, GenMont Biotech ranks better than 83.35% on this metric.
Net margin is calculated as Net Income divided by its Revenue. GenMont Biotech's Net Income for the
three
months ended in Dec. 2025 was NT$24.8 Mil. GenMont Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$100.7 Mil. Therefore, GenMont Biotech's net margin for the quarter that ended in Dec. 2025 was 24.62%.
The historical rank and industry rank for GenMont Biotech's Net Margin % or its related term are showing as below:
TPE:3164'
s Net Margin % Range Over the Past 10 Years
Min: -43.63 Med: 15.16 Max: 38.87
Current: 14.26
TPE:3164's Net Margin % is ranked better than 83.35% of 937
companies
in the Biotechnology industry
Industry Median: -88.29
vs TPE:3164: 14.26
GenMont Biotech (TPE:3164) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
GenMont Biotech Net Margin % Related Terms
GenMont Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for GenMont Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3164 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, GenMont Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech (TPE:3164) has a Net Margin % of 24.62% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on GenMont Biotech and its competitors. This is 62% above median its historical median of 15.16. According to the industry distribution chart, GenMont Biotech ranks #156 out of 937 companies in the Biotechnology industry, placing it in the top 16.6%.
Is GenMont Biotech's Net Margin % too high?
GenMont Biotech's current Net Margin % of 24.62% is 62% above median its 10-year median of 15.16. Based on the distribution chart, GenMont Biotech ranks #156 out of 937 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #156 out of 937 companies for Net Margin %. This places GenMont Biotech in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on GenMont Biotech and its competitors. GenMont Biotech's current Net Margin % is 24.62%, which is 62% above median its own 10-year median of 15.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current Net Margin % is 24.62%, which is 62% above median its 10-year median of 15.16. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current Net Margin % is 24.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24.
GuruFocus considers GenMont Biotech to be Significantly Undervalued.
Key valuation signals for TPE:3164:
Net Margin %: 24.62% (62% above median its 10-year median of 15.16)
GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score
Get the complete analysis for TPE:3164
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
